{"id":"abiraterone-usual","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Adrenal insufficiency"},{"rate":"10-20%","effect":"Hypertension"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Muscle weakness"},{"rate":"5-10%","effect":"Joint pain"}]},"_chembl":{"chemblId":"CHEMBL271227","moleculeType":"Small molecule","molecularWeight":"391.56"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Abiraterone works by inhibiting the enzyme CYP17, which is involved in the production of testosterone. By blocking this enzyme, abiraterone reduces the levels of testosterone in the body, which can slow the growth of prostate cancer cells.","oneSentence":"Abiraterone is an androgen biosynthesis inhibitor that blocks the production of testosterone in the body.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:28:19.088Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic castration-resistant prostate cancer"}]},"trialDetails":[{"nctId":"NCT03348670","phase":"PHASE2, PHASE3","title":"Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms","status":"ACTIVE_NOT_RECRUITING","sponsor":"Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair","startDate":"2023-08-18","conditions":"Prostate Cancer","enrollment":600},{"nctId":"NCT03043807","phase":"PHASE2","title":"A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2017-02-22","conditions":"Prostate Cancer","enrollment":26},{"nctId":"NCT03548246","phase":"PHASE2","title":"Androgen Reduction in Congenital Adrenal Hyperplasia","status":"WITHDRAWN","sponsor":"University of Texas Southwestern Medical Center","startDate":"2023-01","conditions":"Congenital Adrenal Hyperplasia","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ZYTIGA - abiraterone acetate tablet, film coated plus prednisone tablet plus BICALUTAMIDE tablet for Oral"],"phase":"phase_2","status":"active","brandName":"Abiraterone - Usual","genericName":"Abiraterone - Usual","companyName":"Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair","companyId":"han-xu-m-d-ph-d-fapcr-sponsor-investigator-irb-chair","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Abiraterone is a small molecule inhibitor that targets the cytochrome P450 17A1 enzyme, specifically inhibiting its steroid 17-alpha-hydroxylase/17,20 lyase activity. It is used to treat conditions such as prostate cancer and congenital adrenal hyperplasia, and is available in the form of abiraterone acetate.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}